Inotiv, Inc. (NOTV)
| Market Cap | 9.30M -87.8% |
| Revenue (ttm) | 507.36M +5.6% |
| Net Income | -86.97M |
| EPS | -2.53 |
| Shares Out | 34.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 312,549 |
| Open | 0.2684 |
| Previous Close | 0.2700 |
| Day's Range | 0.2600 - 0.2799 |
| 52-Week Range | 0.2158 - 3.3200 |
| Beta | 3.83 |
| Analysts | Strong Buy |
| Price Target | 3.25 (+1,119.06%) |
| Earnings Date | May 11, 2026 |
About NOTV
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the ... [Read more]
Financial Performance
In fiscal year 2025, Inotiv's revenue was $513.02 million, an increase of 4.54% compared to the previous year's $490.74 million. Losses were -$68.63 million, -36.72% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for NOTV stock is "Strong Buy." The 12-month stock price target is $3.25, which is an increase of 1,119.06% from the latest price.
News
Inotiv Quarterly report: Q2 2026
Inotiv has published its Q2 2026 quarterly earnings report on May 11, 2026.
Inotiv provides notice regarding cybersecurity incident
Inotiv (NOTV) is providing public notice regarding its cybersecurity incident that it became aware of on August 8, 2025. “As previously described in the Company’s Current Report on Form 8-K…
Inotiv Provides Notice Regarding Cybersecurity Incident
WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
Inotiv price target lowered to $1.50 from $3 at Lake Street
Lake Street analyst Frank Takkinen lowered the firm’s price target on Inotiv (NOTV) to $1.50 from $3 and keeps a Buy rating on the shares. Fiscal Q1 revenue was in…
Inotiv Slides: Investor presentation
Inotiv has posted slides in relation to its latest quarterly earnings report, which was published on February 9, 2026.
Inotiv Earnings Call Transcript: Q1 2026
Q1 2026 delivered strong DSA growth and margin improvement, offset by RMS weakness from lower NHP volumes. Cost reduction and site optimization efforts are underway, with innovation and new collaborations supporting future growth. No formal FY 2026 guidance was provided.
Inotiv Quarterly report: Q1 2026
Inotiv has published its Q1 2026 quarterly earnings report on February 9, 2026.
Inotiv Earnings release: Q1 2026
Inotiv released its Q1 2026 earnings on February 9, 2026, summarizing the period's financial results.
Inotiv reports Q1 EPS (83c) vs. ($1.02) last year
Reports Q1 revenue $120.9M vs. $119.9M last year. Robert Leasure Jr., President and Chief Executive Officer, commented, “During the first quarter of fiscal 2026, we continued to execute on our…
Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update
WEST LAFAYETTE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery ...
Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026
WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
Inotiv to leverage LifeNet Health’s TruVivo in translational drug discovery
Inotiv (NOTV) announced a strategic initiative to leverage LifeNet Health’s proprietary TruVivo within its Discovery and Translational Sciences business. LifeNet Health has developed the patented TruV...
Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery
WEST LAFAYETTE, Ind., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical dr...
Inotiv partners with Vugene to advance AI-driven drug discovery
Inotiv (NOTV) and Vugene, a multi-omics data analysis company providing advanced artificial intelligence and machine learning solutions for biomedical research, announced a strategic collaboration des...
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities
WEST LAFAYETTE, Ind., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization (CRO) specializing in nonclinical and analyti...
Inotiv price target lowered to $3 from $5 at Lake Street
Lake Street analyst Frank Takkinen lowered the firm’s price target on Inotiv (NOTV) to $3 from $5 and keeps a Buy rating on the shares. The firm, which thinks the…
Inotiv Earnings Call Transcript: Q4 2025
Q4 and FY25 saw robust revenue and margin growth, led by DSA, despite a cybersecurity incident. RMS site consolidation and IT streamlining drove cost savings, while legal settlements and refinancing efforts improved the balance sheet. DSA demand and awards remain strong.
Inotiv Annual report: Q4 2025
Inotiv has published its Q4 2025 annual report on December 3, 2025.
Inotiv Earnings release: Q4 2025
Inotiv released its Q4 2025 earnings on December 3, 2025, summarizing the period's financial results.
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update
– Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million– Fiscal 2025 revenue increased 4.5% to $513.0 million– Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million– Fis...
Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™
Building a Unified, Client-Focused, Early Stage CRO Through Strategic Expansion and Service Development Powers 448% Revenue Growth from Fiscal Year 2021 to Fiscal Year 2024 Building a Unified, Client-...
Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025
WEST LAFAYETTE, Ind., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
Inotiv Transcript: Jefferies London Healthcare Conference 2025
Q4 saw strong revenue and DSA award growth, with operational efficiencies from integration and site consolidation. Pricing has firmed, margins are improving, and NHP activity stabilized. Debt restructuring and cyber recovery efforts are ongoing, with systems fully restored.
Closing Bell Movers: Inotiv surges after quarterly results
U.S. equity futures were marginally higher following a broad selloff during the session amid concerns about AI valuations and upcoming jobs numbers. Investors are also weighing the possibility of fewe...
Inotiv sees Q4 revenue $137.5M-$138.5M, consensus $133.35M
Book-to-bill ratio for Q4 is anticipated to be approximately 1.08x for the DSA services business. Anticipated DSA backlog of approximately $138M at September 30 compared to $129.9M at September 30,…